Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 9/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.51 |
| ▸ | TSHR | P16473 | 3/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.49 |
| ▸ | RECQL | P46063 | 1/20 | 0.49 |
| ▸ | FKBP1A | P62942 | 2/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1704641 | 1.00 | ALDH1A1 (0.51) | ALDH1A1KDM4ETSHRMAPK1RECQL | |
| SCHEMBL14925980 | 1.00 | ALDH1A1 (0.51) | ALDH1A1KDM4ETSHRMAPK1RECQL | |
| SCHEMBL12125004 | 0.95 | ALDH1A1 (0.56) | ALDH1A1KDM4ETSHRMAPK1RECQL | |
| SCHEMBL7295807 | 0.86 | ALDH1A1 (0.49) | ALDH1A1KDM4ETSHRMAPK1RECQL | |
| SCHEMBL18948659 | 0.86 | KDM4E (0.51) | ALDH1A1KDM4ETSHRMAPK1RECQL | |
| SCHEMBL1953383 | 0.85 | KDM4E (0.50) | ALDH1A1KDM4ETSHRMAPK1RECQL | |
| SCHEMBL1953381 | 0.85 | KDM4E (0.50) | ALDH1A1KDM4ETSHRMAPK1RECQL | |
| SCHEMBL8977442 | 0.84 | LTA4H (0.47) | ALDH1A1KDM4EFKBP1APOLB | |
| SCHEMBL3315632 | 0.84 | LTA4H (0.47) | ALDH1A1KDM4EFKBP1APOLB | |
| SCHEMBL12677313 | 0.84 | LTA4H (0.47) | ALDH1A1KDM4EFKBP1APOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230242532-A1 | TETRACYCLIC PYRIMIDINONE COMPOUND, PREPARATION METHOD THEREFOR, AND COMPOSITION AND USE THEREOF | NEUSCO BIOTECH LIMITED (CN) | 2023-08-03 | — | — | US | disclosed |
| CN-112574221-B | Tetracyclic pyrimidinone compounds, preparation method, composition and application thereof | 上海纽思克生物科技有限公司 | 2022-03-04 | — | — | CN | disclosed |
| CN-112574221-A | Tetracyclic pyrimidinone compounds, preparation method, composition and application thereof | 上海纽思克生物科技有限公司 | 2021-03-30 | — | — | CN | disclosed |
| EP-2704720-B1 | PYRUVATE KINASE R ACTIVATORS FOR USE IN THERAPY | AGIOS PHARMACEUTICALS INC (US) | 2019-08-07 | — | — | EP | disclosed |
| EP-2658543-B1 | PYRUVATE KINASE M2 (PKM2) ACTIVATORS FOR USE IN THERAPY | AGIOS PHARMACEUTICALS INC (US) | 2019-02-20 | — | — | EP | disclosed |
| US-9404081-B2 | Pyruvate kinase activators for use in therapy | AGIOS PHARMACEUTICALS, INC. (US) | 2016-08-02 | — | — | US | disclosed |
| US-9199968-B2 | Therapeutic compounds and compositions | AGIOS PHARMACEUTICALS, INC. (US) | 2015-12-01 | — | — | US | disclosed |
| EP-2000126-B1 | HAIR DYEING COMPOSITION | KAO CORP (JP) | 2015-08-19 | — | — | EP | disclosed |
| US-20150183760-A1 | THERAPEUTIC COMPOUNDS AND COMPOSITIONS | AGIOS PHARMACEUTICALS, INC (US) | 2015-07-02 | — | — | US | disclosed |
| EP-2000125-B1 | HAIR DYEING COMPOSITION | KAO CORP (JP) | 2015-06-10 | — | — | EP | disclosed |
| WO-2012151452-A1 | PYRUVATE KINASE ACTIVATORS FOR USE IN THERAPY | AGIOS PHARMACEUTICALS, INC (US) | 2012-11-08 | — | — | WO | disclosed |
| WO-2012092442-A1 | THERAPEUTIC COMPOUNDS AND COMPOSITIONS | AGIOS PHARMACEUTICALS, INC. (US) | 2012-07-05 | — | — | WO | disclosed |
| US-20120172349-A1 | THERAPEUTIC COMPOUNDS AND COMPOSITIONS | SCHRODINGER, LLC. | 2012-07-05 | — | — | US | disclosed |
| US-7736396-B2 | mixing the first part containing an oxidative dye intermediate and second part containing hydrogen peroxide oxidizer immediately before use, applying mixture to the hair, leaving the hair for 1 to 60 minutes, then rinsing; 3-pyrrolidinyl-1,2,2-triethylpiperidine gives less damage to the hair; bleaching | KAO CORPORATION (JP) | 2010-06-15 | — | — | US | disclosed |
| US-20090265864-A1 | mixing the first part containing an oxidative dye intermediate and second part containing hydrogen peroxide oxidizer immediately before use, applying mixture to the hair, leaving the hair for 1 to 60 minutes, then rinsing; 3-pyrrolidinyl-1,2,2-triethylpiperidine gives less damage to the hair; bleaching | KAO CORPORATION (JP) | 2009-10-29 | — | — | US | disclosed |
| US-7582124-B2 | mixing the first part containing an oxidative dye intermediate and second part containing hydrogen peroxide oxidizer immediately before use, applying mixture to the hair, leaving the hair for 1 to 60 minutes, then rinsing; 3-pyrrolidinyl-1,2,2-triethylpiperidine gives less damage to the hair; bleaching | KAO CORPORATION (JP) | 2009-09-01 | — | — | US | disclosed |
| US-20090081146-A1 | mixing the first part containing an oxidative dye intermediate and second part containing hydrogen peroxide oxidizer immediately before use, applying mixture to the hair, leaving the hair for 1 to 60 minutes, then rinsing; 3-pyrrolidinyl-1,2,2-triethylpiperidine gives less damage to the hair; bleaching | KAO CORPORATION (JP) | 2009-03-26 | — | — | US | disclosed |
| EP-2000125-A9 | HAIR DYEING COMPOSITION | Kao Corporation (JP) | 2009-03-18 | — | — | EP | disclosed |
| EP-2000125-A2 | HAIR DYEING COMPOSITION | Kao Corporation (JP) | 2008-12-10 | — | — | EP | disclosed |
| EP-2000126-A1 | HAIR DYEING COMPOSITION | Kao Corporation (JP) | 2008-12-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120172349-A1 | THERAPEUTIC COMPOUNDS AND COMPOSITIONS | PDK1, PDK2, PDK3 | ALDH1A1 1326/4885KDM4E 766/4885TSHR 2017/4885 |
| US-20150183760-A1 | THERAPEUTIC COMPOUNDS AND COMPOSITIONS | PDK1, PDK2, PDK3 | ALDH1A1 1326/4885KDM4E 766/4885TSHR 2017/4885 |
| US-20090265864-A1 | mixing the first part containing an oxidative dye intermediate and second part containing hydrogen peroxide oxidizer immediately before use, applying mixture to the hair, leaving the hair for 1 to 60 minutes, then rinsing; 3-pyrrolidinyl-1,2,2-triethylpiperidine gives less damage to the hair; bleaching | GPX4, GPX1, POLR1C | ALDH1A1 175/4885KDM4E 1899/4885TSHR 701/4885 |
| US-20230242532-A1 | TETRACYCLIC PYRIMIDINONE COMPOUND, PREPARATION METHOD THEREFOR, AND COMPOSITION AND USE THEREOF | PLA2G1B, PLA2G5, PLA2G7 | ALDH1A1 820/4885KDM4E 4433/4885TSHR 4050/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.